SML3053
CC-3060
≥98% (HPLC)
Synonym(s):
4-[(2-Benzofuranylmethyl)amino]-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, 4-[(Benzofuran-2-ylmethyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C22H17N3O5
CAS Number:
Molecular Weight:
403.39
UNSPSC Code:
12352200
NACRES:
NA.77
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C1NC(C(CC1)N2C(C3=C(C2=O)C(NCC4=CC5=C(C=CC=C5)O4)=CC=C3)=O)=O
InChI
1S/C22H17N3O5/c26-18-9-8-16(20(27)24-18)25-21(28)14-5-3-6-15(19(14)22(25)29)23-11-13-10-12-4-1-2-7-17(12)30-13/h1-7,10,16,23H,8-9,11H2,(H,24,26,27)
InChI key
GRICLJZNEMDVMA-UHFFFAOYSA-N
Biochem/physiol Actions
CC-3060 is a cell-permeable pomalidomide analog that acts as a potent, efficacious and dose-dependent promoter of CRL4CRBN-mediated ZBTB16 (Promyelocytic Leukemia Zinc Finger protein or PLZF) proteasomal degradation (DC50 = 0.47 nM and a ymin of 28 in HT-1080 ZBTB16-ePL cells). CC-3060 is shown to directly interact with the C2H2 ZnF1 domain, form a ternary complex with CRBN/ZBTB16 and stimulate ZBTB16-RARα robust degradation (Ymin of 20 in RAR?-ZBTB16-ePL cells). Also facilitates degradation of CRBN neosubstrates IKZF1, ZFP91, and ZNF276 with no effect on GSPT1 and CSNK1A1.
cell-permeable pomalidomide analog that acts as a potent, efficacious and dose-dependent promoter of CRL4CRBN-mediated ZBTB16 proteasomal degradation
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Aberra Fura et al.
Drug metabolism and disposition: the biological fate of chemicals, 37(6), 1164-1171 (2009-03-03)
Saxagliptin is a potent, selective, reversible dipeptidyl peptidase 4 (DPP4) inhibitor specifically designed for extended inhibition of the DPP4 enzyme and is currently under development for the treatment of type-2 diabetes. The pharmacokinetics of saxagliptin were evaluated in rats, dogs
Mary E Matyskiela et al.
ACS chemical biology, 15(12), 3149-3158 (2020-11-19)
There is a growing interest in using targeted protein degradation as a therapeutic modality in view of its potential to expand the druggable proteome. One avenue to using this modality is via molecular glue based Cereblon E3 Ligase Modulating Drug
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML3053-25MG | 04065266689518 |
| SML3053-5MG | 04065266689525 |